Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 118

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 118
---
 new agreement with the sublicensee upon substantially the same terms as the sublicense as long as the terms are
amended such that Yissum is not subject to any obligation or liability which are not included in, or in greater scope than, Yissum’s
obligations or liabilities under the license agreement; or (b) require the sublicensee to enter into a new license agreement on substantially
the same terms and conditions as those contained in the license agreement.

<div align='center'>75</div>

We have the first right to prepare, file, prosecute
and maintain any patent applications and patents in respect of the licensed technology and any part thereof, at our expense, subject to
certain conditions. We are required to file each licensed patent application at least in the United States, Europe and Japan. We are also
required to take action, in reasonable commercial circumstances and after consultation with patent counsel, in the prosecution, prevention
or termination of any infringement of patents licensed under the agreement. We are responsible for the expenses of any patent infringement
suit that we bring, including the expenses incurred by Yissum in connection with such suits. We are entitled to reimbursement from any
awards or settlements recovered in such suit or in the settlement thereof for all costs and expenses involved in the prosecution of any
such suit. If we elect not to pursue any action in connection with infringement and Yissum in good faith disagrees with us that it is
in the mutual best interest of both parties not to pursue any such action, then, at our election, we may either allow Yissum to pursue
such actions, at Yissum’s expense, or pay Yissum the royalties that Yissum would otherwise receive from us attributable to lost
sales resulting from such alleged infringement

Research and Option Agreement with Yissum for the ARB Blockers

On October 25, 2023, we entered into Research
and Option Agreement with Yissum with respect to the nanoparticles-based formulation of angiotensin receptor blockers (ARB) for intravenous
administration. Under the agreement, we shall provide funding for research and development studies to be performed by researchers at Hebrew
University related to the formulation, preparation and characterization of nanoparticles-based formulation of angiotensin receptor blockers
(ARB) for intravenous administration. In consideration for the research services, we agreed to pay research service fees of $150,000,
in periodic payments subject to completing specified milestones. All data generated from the provision of the services, including any